Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.
We continue to support MDV3100 through a growing body of research and clinical posters and papers.Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 2004;10(1):33-39. Chen Y, Scher HI, Clegg NJ. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncology. 2009. 10(10): 981-91. Scher H, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1—2 study. The Lancet. 2010; 375(9724):1409-10. Tran C, et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science. 2009;324:787-790. |
 |
 |
| Medivation © 2012 |